Clinical trials: Colorectal Tumor
Advanced Solid Tumor, Gynecologic Cancer
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including…
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer
- Trial name
- NCT04682431
- Testing
- PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3
- Where
- 17 sites in United States
- Volunteers
- 127 people
- Sponsor
- Ikena Oncology
Colorectal Cancer, Gastro Esophageal Junctional Cancer
IKS04 Regimen in Advanced Solid Tumors That Express CA242
This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further…
- Conditions
- Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
- Trial name
- NCT07738939
- Testing
- IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Iksuda Therapeutics Ltd.
Colorectal Cancer (CRC), Colon Cancer Liver Metastases
Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases
The goal of this clinical trial is to learn if a new injectable drug (IP-001), administered after standard liver tumor ablation, can help prevent cancer from returning in people (males/females, ≥18 years old) with colorectal…
- Conditions
- Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer, Rectal Cancer With Liver Metastases
- Trial name
- INJECTABL-3 (NCT07321847)
- Testing
- 1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water, 1.0% IP-001 for Injection, a 1 mg/mL solution of IP-001 in water., Microwave (thermal) tumor ablation
- Volunteers
- 717 people
- Sponsor
- Immunophotonics, Inc.
Metastatic Colorectal Cancer
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
This Study is in two parts, the first part is to make sure that combining a potential new treatment, cediranib (AZD2171), with a standard treatment (FOLFOX) for metastatic colorectal cancer is safe.
- Trial name
- NCT00494221
- Testing
- AZD2171, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- 2 sites in Japan
- Volunteers
- 172 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
This study will evaluate the safety, tolerability, and preliminary antitumor activity of CAN04 both as a monotherapy and in combination with standard of care treatment in subjects with solid cancer tumors.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer
- Trial name
- CANFOUR (NCT03267316)
- Testing
- CAN04, Cisplatin, Gemcitabine
- Where
- 25 sites in Austria, Belgium and 9 more
- Volunteers
- 167 people
- Sponsor
- Cantargia AB
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis
- Trial name
- NCT05952947
- Testing
- HRYZ-T101 Injection, Fludarabine + Cyclophosphamide
- Where
- China
- Volunteers
- 32 people
- Sponsor
- HRYZ Biotech Co.
Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors…
- Conditions
- Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
- Trial name
- Luca-1 (NCT07705334)
- Testing
- SHY-ONC6
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- SHY Therapeutics
Metastatic Colorectal Cancer
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
This study will compare the safety and efficacy of dalotuzumab (MK-0646) in combination with cetuximab and irinotecan in treating participants with wild type KRAS (wtKRAS) metastatic colorectal cancer (CRC) compared to cetuximab…
- Trial name
- NCT00614393
- Testing
- dalotuzumab, irinotecan hydrochloride, cetuximab
- Volunteers
- 558 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors, Ovarian Cancer
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer
- Trial name
- NCT04408599
- Testing
- NC410
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- NextCure, Inc.
Colorectal Cancer
A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
This study will assess the efficacy and safety of intravenous Avastin in combination with chemotherapy regimens as second-line treatment of metastatic cancer of the colon or rectum.
- Trial name
- NCT01181609
- Testing
- bevacizumab [Avastin]
- Where
- 16 sites in France
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Colon Cancer Stage I
A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study
This is a Phase I, open-label study to explore the safety profile and to find the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of Magicell-NK in subjects diagnosed with stage I or stage IIa colon cancer post…
- Trial name
- NCT05394714
- Testing
- Magicell-NK contains NK cells suspended in 100 mL normal saline
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- Medigen Biotechnology Corporation
Metastatic Colorectal Cancer
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
The purpose of this study is to determine the treatment effect of panitumumab in combination with FOLFOX compared to FOLFOX alone as first line therapy for metastatic colorectal cancer
- Trial name
- NCT00364013
- Testing
- Panitumumab, FOLFOX regimen
- Volunteers
- 1,183 people
- Sponsor
- Amgen
Clear Cell Renal Cell Carcinoma
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum…
- Trial name
- NCT05433142
- Testing
- XmAb819
- Where
- 26 sites in United States, Belgium and 3 more
- Volunteers
- 307 people
- Sponsor
- Xencor, Inc.
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06704724
- Testing
- PF-07985045, Gemcitabine, Nab-paclitaxel
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Pfizer
Cervical Cancer, Head and Neck Cancer
RTX-321 Monotherapy in Patients With HPV 16+ Tumors
This is an open-label, multicenter, multiple-ascending dose, FIH, Phase 1 study of RTX-321 for the treatment of patients that are HLA-A*02:01 positive with persistent, recurrent, or metastatic, unresectable, HPV 16+ cancers.
- Conditions
- Cervical Cancer, Head and Neck Cancer, Anal Cancer
- Trial name
- NCT04672980
- Testing
- RTX-321
- Where
- 10 sites in United States
- Volunteers
- 9 people
- Sponsor
- Rubius Therapeutics
Breast Cancer, Breast Neoplasms
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors.
- Conditions
- Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer
- Trial name
- NCT00600496
- Testing
- AZD6244, Dacarbazine, Erlotinib
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Solid Tumor, Breast Cancer
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant…
- Conditions
- Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT05989724
- Testing
- SON-DP
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Qurgen Inc.
BRAF V600E-mutant Metastatic Colorectal Cancer
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in…
- Trial name
- BEACON CRC (NCT02928224)
- Testing
- Encorafenib, Binimetinib, Cetuximab
- Where
- 418 sites in United States, Argentina and 25 more
- Volunteers
- 702 people
- Sponsor
- Pfizer
Colorectal Cancer, Pancreatic Cancer
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus…
- Trial name
- NCT03184870
- Testing
- BMS-813160, Nivolumab, Nab-paclitaxel
- Where
- 40 sites in United States, Australia and 4 more
- Volunteers
- 332 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
A Study of ABT-165 in Subjects With Solid Tumors
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and…
- Trial name
- NCT01946074
- Testing
- paclitaxel, FOLFIRI, ABT-165
- Where
- 10 sites in United States
- Volunteers
- 101 people
- Sponsor
- AbbVie